Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $21.3333.

TBPH has been the topic of a number of recent research reports. BTIG Research reaffirmed a “buy” rating and set a $21.00 price target on shares of Theravance Biopharma in a research report on Friday, March 20th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. HC Wainwright raised their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, TD Cowen raised their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Theravance Biopharma during the 3rd quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the period. CIBC Private Wealth Group LLC increased its holdings in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 0.5%

Shares of NASDAQ TBPH opened at $16.10 on Tuesday. The firm has a market cap of $828.99 million, a P/E ratio of 7.93 and a beta of 0.17. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The business’s 50 day moving average is $16.97 and its 200-day moving average is $17.00.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.